MONARCH: a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Summary
- Miricorilant, an oral, nonsteroidal selective glucocorticoid receptor modulator (SGRM), may offer a promising new strategy for the treatment of MASH
- Previous clinical trials have shown that twice-weekly miricorilant 100 mg was safe, well tolerated, effectively lowered liver fat, and improved other hepatic, lipid, and glycemic markers
- MONARCH is a phase 2b, double-blind, placebo-controlled, randomized study evaluating efficacy and safety of miricorilant in patients with biopsy-confirmed or presumed noncirrhotic MASH
- MONARCH is actively enrolling at sites across the United States, Mexico, and India